Cancer Biomarker | ECS progastrin | Suisse

ECS progastrin SA is a subsidiary of

Progastrine Invest SCSp – Cancer Control Funding Fund

11 côte d'Eich, L1450,

Luxembourg City - Grand Duchy of Luxembourg

Progastrine invest

11 côte d'Eich,

L1450 Luxembourg ville

Grand Duché du Luxembourg

ECS progastrin Lab

Chemin de la Meunière 12

Prilly 1008

Suisse

Progastrin Manufacturing

Chemin de la Meunière 12

Prilly 1008

Suisse

Progastrine et cancers

11 côte d'Eich,

L1450 Luxembourg ville

Grand Duché du Luxembourg

Eurobiodev

2040 avenue du Père Soulas

34000 Montpellier

France

Progastrine Invest SCSp and its subsidiaries

  • focus on innovation in cancer screening, diagnosis and treatment,

  • hold the rights to the first circulating progastrin assay, identified as a new marker associated with cancer. This dosage helps to screen for cancer even at early stages and to monitor therapies,

  • are the holders of the rights to the cancer therapy project with an anti-progastrin antibody.

 

For ethical reasons and out of respect for practitioners, health institutions, populations and regulations in force in all countries where they operate, Progastrine Invest SCSp and its subsidiaries pay extreme attention to the information they publicly provide.

 

The management of Progastrine Invest SCSp, its subsidiaries and their scientific committee would like to remind you that only information published on the official communication media of the group's companies can be considered as confirmed and authorised.

© 2018 ECS progastrin

One in two people will be diagnosed with cancer during his/her lifetime

Imagine if it was possible with a blood-based biomarker test to help and enable doctors:

  • to detect multiple cancers susceptibility

  • to detect cancer progression or relapse

How could it impact a patient’s journey with cancer?

We are here to help you discover that possibility with two new tools for physicians:

Logo_DxPG80-Smart_20190510.png
Logo_DxPG80-Lab_20190510.png

Cancer facts

One in two people will be diagnosed with cancer during his/her lifetime

Cancer susceptibility detection is the key

Today screening tests:

  • can not detect several types of cancer

  • do not allow efficient detection of tumors at early stages

Reliable detection of cancer at an early stage before symptoms appear has the potential to dramatically decrease global cancer mortality.

Innovative answer

1.

ECS progastrin's approach

An efficient screening test should meet the following criteria :

RELIABLE

REPRODUCTIBLE

AFFORDABLE

VALID FOR MULTIPLE CANCERS

SIMPLE

 
 
 
 

2.

A new tool to help physicians to detect multiple cancers susceptibility at early stages

ECS-progastrin has developed the first true test for helping early cancer screening working for multiple cancers and meeting all these criteria. Called DxPG80, this IVD test is able to detect a specific biomarker in the blood: hPG80 (Progastrin).

In almost all types of cancers, at the earliest stages of development, there is an uncontrolled activation of the Wnt oncogenic pathway. This uncontrolled activation of the Wnt oncogenic pathway is vital for the cancer cells to grow and survive. It induces the expression of multiple genes required for the cancer cells to grow and survive. Among these multiple genes, there is the gene coding for our target: Progastrin.

DxPG80 IVD test is CE marqued under  the project name cancerREAD. Regulatory revisions are ongoing.

 

3.

Efficient technology

Under pathological condition:

However, in tumors, progastrin produced by cancer cells is not maturated in gastrin, leading to the secretion of progastrin and thus to its presence in the blood. Therefore we can specifically detect Progastrin in the blood of persons having a cancer.

Under physiological condition:

Progastrin is a pro-hormone that is processed in gastrin, an hormone that is secreted during digestion by specific cells of the stomach, that stimulates the normal secretion of gastric acid. In these physiological conditions, and outside the digestion time, progastrin is not present in the blood.

DxPG80 IVD test is based on the ELISA technique that is the most reliable and the most routinely used assay to detect biomarkers on the blood.

ELISA is a test that combines the specificity of antibodies with the sensitivity of enzyme assays, by using antibodies coupled to an easily-assayed enzyme. A color change shows the presence of the biomarker.

 

Scientific Committee

Éric Thieulin

President

Dominique Joubert-Floch, Ph.D. in biology

Senior Scientific Consultant

Alexandre Prieur,
Ph.D. in oncology

Chief Scientific Officer

François Dupoteau

Chief Technology Officer

 

To share its medical & scientific results with you, ECS progastrin is proud to be present at major cancer congresses

 

Secure your future

It's time to control cancer

Contact us

ECS progastrin

Chemin de la Meunière 12

Prilly 1008 Suisse